The purpose is to determine if after 24 weeks of oral daily administration, there will be a greater mean reduction from baseline in glycosylated hemoglobin (HbA1c) achieved with Dapagliflozin 10 mg plus insulin compared to placebo plus insulin in subjects with type 2 diabetes.

Inclusion Criteria:

• Subjects must have type 2 diabetes with inadequate glycemic control, defined as HbA1c ≥ 7.5% and ≤ 11.0% obtained at screening visit
• Subjects must be taking a stable mean dose of ≥ 20 IU injectable insulin daily for at least 8 weeks prior to enrollment

Inclusion criteria for randomization:

HbA1c ≥ 7.5 and ≤ 10.5% at Day -14

Exclusion Criteria:

• Treatment with more than two oral antidiabetic (OAD) agents within 6 weeks of Enrollment
• History of diabetic ketoacidosis of hyperosmolar nonketotic coma
• Clinically diagnosed Type 1 diabetes mellitus
• Congestive heart failure defined as New York Heart Association (NYHA) stage III and IV
• Severe uncontrolled hypertension defined as systolic blood pressure (SBP) ≥ 180 mmHg and/or diastolic blood pressure (DBP) ≥ 110 mmHg
• History of unstable or rapidly progressing renal disease
• History of severe hepatobiliary disease
• Mallingancy within 5 years of the screening/enrollment visit